Go back to the main page.
Transforming Today's Science Into Tomorrow's Cures
Samaritan's collaborative researchers have made important patented discoveries in the fields of, central nervous system diseases, such as, Alzheimer's disease; cancer; cardiovascular disease; and infectious diseases, such as, AIDS, and Hepatitis C. These discoveries have positioned us with a rich pipeline of new drugs with novel mechanisms of actions to develop.
Samaritan Pharmaceuticals, Inc. is an entrepreneurial biopharmaceutical company focused on the development and marketing of innovative therapeutics. At Samaritan Pharmaceuticals our mission has been to create life-saving drugs for people suffering from AIDS, Alzheimer’s, heart disease and cancer. View all the latest press releases and news articles focused on Samaritan Pharmaceuticals, Inc. These publications, called peer-reviewed journals, are scholarly periodicals requiring each article submitted be judged by an independent panel of experts (scientific peers) to authenticate the accuracy of the material. The number of articles printed and the variety of publications accepting the article serve to underscore the legitimacy of information. Samaritan has collaborative relationships with other pharmaceutical companies to commercialize branded approved prescription products in selected niche territories, such as, in Greece, Albania, Bosnia, Bulgaria, Croatia, Cyprus, Czech Republic, Egypt, FYROM, Hungary, Montenegro, Poland, Romania, Serbia, Slovakia, Slovania, Syria and Turkey. Before a drug can be offered to the public it must go through several phases of rigorous testing to make sure it is safe, efficient and does what it says it can do. The testing is mandated and overseen by the U.S. Food and Drug Administration (FDA) which is part of the U.S. Department of Health and Human Services. SAMARITAN PIPELINE - (MECHANISM OF ACTION VIDEOS)
Go back to the main page. Contact Samaritan Pharmaceuticals, Inc. Find what you are looking for in our website.
Nov/Dec - 2007 Newsletter
  • Samaritan Presents Favorable Caprospinol Data At Alzheimer's Drug Development Summit
  • International Ranking of Universities: McGill Cracks Distinguished Dozen - Times Higher Ed Rankings
  • Caprospinol May Restore Memory With Alzheimer's Disease
  • Samaritan Retains The Investor Relations Group of New York
Oct - 2007 Newsletter
  • Samaritan adds 11th Revenue Generating Product...
  • Samaritan to host 2007 Annual Meeting Oct. 23...
  • World Renowned HIV Researcher Dr. Hildreth joins Samaritan...
  • Samaritan CEO speaks at Biotech in Europe Investor Forum...
  • Stroke - When the Brain Attacks
Aug - Sep 2007 Newsletter
  • Samaritan Files Patent For Tumor Inhibiting Cancer Drugs...
  • Samaritan Files Patent For Method to Identify Anti-Tumor Drugs...
  • Date and Location for Annual Shareholder Meeting is Set...
Aug - Sep 2007 Newsletter
  • Samaritan Files Patent For Tumor Inhibiting Cancer Drugs...
  • Samaritan Files Patent For Method to Identify Anti-Tumor Drugs...
  • Date and Location for Annual Shareholder Meeting is Set...
Jun - Jul 2007 Newsletter
  • On the horizon with Oral Entry Inhibitors
  • Green Light: The Pharmaplaz agreement
  • New drug on pipeline: Replagal
Apr - May 2007 Newsletter
  • Samaritan / Pharmaplaz SP-01A Deal
  • SP-6300 Fights Cushing's Syndrome
  • SP-10 Powerful Antiviral
Feb - Mar 2007 Newsletter
  • In-Licencing New Products in 2007
  • New Website for the New Year
  • Samaritan's Pipeline is Growing Too!
Dec - Jan 2006 Newsletter
  • Samaritan's Alzheimer's Drug receives IND from FDA
  • Online Video Explains SP-233 Action
  • 25 Years of AIDS
  • Samaritan Pipelines
 

Partnering
Opportunities

Samaritan Email
News Alert Signup:
Name:
Email:
Address:
Address:
City:
State:
Zip:
Phone: